Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clobetasol + spironolactone
- Development stage
- Phase 2
- Lead developer
- Trade
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Clobetasol + spironolactone is a topical combination medication that has been studied for preventing skin atrophy associated with corticosteroid use. Clobetasol is a potent topical glucocorticoid that can cause skin thinning (epidermal atrophy) as a side effect. Spironolactone, a mineralocorticoid receptor antagonist, has been shown to limit this clobetasol-induced skin atrophy when co-applied. The combination works by allowing the therapeutic benefits of clobetasol while the spironolactone component helps protect against the skin-thinning side effects through mineralocorticoid receptor blockade.
02
Targets
GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on clobetasol + spironolactone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clobetasol + spironolactone.